August 17, 2018
Rose
A lack of understanding about the disease's physiology makes creating new medicines difficult. “So we hope to revolutionize the way schizophrenics are being treated. … We hope to give these people their lives back," Remy Luthringer, CEO of Boston-based Minerva Neurosciences, tells Stat. In other biotech and pharmaceutical news: companies thrive in Minnesota. And production resumes at a troubled Pfizer plant.
from Kaiser Health News https://ift.tt/2w9d8ch
August 17, 2018
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Total Hospital Charges From Coronavirus Treatments Projected To Soar Into The Hundreds Of Billions- Under Financial Strain, Community Health Centers Ramp Up Coronavirus Response
- Not So Fast Using CPAPs In Place Of Ventilators. They Could Spread The Coronavirus.
- Advocates Irate Over Government’s Unwillingness To Name 140 Nursing Homes Hit By Pandemic
- Research Roundup: Medicaid Eligibility, ICU Infection Rates, Heartburn Drugs’ Side Effects, And More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment